Tourmaline Bio, Inc. – NASDAQ:TRML

Add to watchlist

$22.37

+1.69

+8.17%

Market closed

Open in 2 days

+38.70%

month

+38.70%

quarter

-27.08%

year

Market Cap	532.85M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Tourmaline Bio Stock Forecast

M Q Y

Last Year

$50

Potential upside: 123.51%

Analysts Price target
Financials & Ratios estimates

Tourmaline Bio, Inc. (NASDAQ:TRML): Profit margin
2020	0	-22.70M
2023	0	-42.12M

Tourmaline Bio, Inc. (NASDAQ:TRML): Earnings per share (EPS)
2023-11-14	-0.94	-1.64

Tourmaline Bio, Inc. (NASDAQ:TRML): Debt to assets
2023	210295000	5.25M	2.5%

Tourmaline Bio, Inc. (NASDAQ:TRML): Cash Flow
2023	-28.08M	3.84M	156.72M

Tourmaline Bio alternative data

Tourmaline Bio, Inc. (NASDAQ:TRML): Employee count
Nov 2023	19
Dec 2023	19
Jan 2024	19
Feb 2024	19
Mar 2024	44
Apr 2024	44
May 2024	44
Jun 2024	44
Jul 2024	58
Dec 2024	74

Tourmaline Bio
Insider Trading

Tourmaline Bio, Inc. (NASDAQ:TRML): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	100000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value	Source
Purchase	29 Jan 2024	MCDADE MARK director director	Common Stock	100,000	$32.5	$3,250,000

TRML insider trading transactions

Tourmaline Bio
Latest News

Tuesday, 10 December 2024
08:30	Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day	globenewswire.com
Thursday, 14 November 2024
07:30	Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024	globenewswire.com
Thursday, 7 November 2024
07:30	Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights	globenewswire.com
Thursday, 31 October 2024
07:30	Tourmaline Bio to Present at Upcoming Investor Conferences	globenewswire.com
Tuesday, 15 October 2024
07:30	Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024	globenewswire.com
Sunday, 13 October 2024
10:29	Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting	seekingalpha.com
Friday, 11 October 2024
07:30	Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress	globenewswire.com
Tuesday, 8 October 2024
07:30	Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board	globenewswire.com
Tuesday, 3 September 2024
07:45	Tourmaline Bio to Present at Upcoming Investor Conferences	globenewswire.com
Thursday, 8 August 2024
07:30	Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights	globenewswire.com
Friday, 2 August 2024
16:30	Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024	globenewswire.com
Thursday, 27 June 2024
08:05	Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer	globenewswire.com
Thursday, 23 May 2024
07:10	Tourmaline Bio to Present at the Jefferies Global Healthcare Conference	globenewswire.com
Thursday, 16 May 2024
07:00	Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial	globenewswire.com
Monday, 13 May 2024
07:00	Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights	globenewswire.com
Tuesday, 19 March 2024
07:00	Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	globenewswire.com
Friday, 15 March 2024
09:51	Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going	Zacks Investment Research
Tuesday, 27 February 2024
07:30	Tourmaline Bio to Present at Upcoming Investor Conferences	GlobeNewsWire
Thursday, 8 February 2024
09:51	What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'	Zacks Investment Research
Thursday, 1 February 2024
08:00	Tourmaline Bio to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	GlobeNewsWire
Wednesday, 1 November 2023
14:09	Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6	Seeking Alpha
08:00	Tourmaline Bio to Present at Upcoming Investor Conferences	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Tourmaline Bio stock today?

One share of Tourmaline Bio stock can currently be purchased for approximately $22.37.
When is Tourmaline Bio's next earnings date?

Unfortunately, Tourmaline Bio's (TRML) next earnings date is currently unknown.
Does Tourmaline Bio pay dividends?

No, Tourmaline Bio does not pay dividends.
How much money does Tourmaline Bio make?

Tourmaline Bio has a market capitalization of 532.85M. Tourmaline Bio made a loss 42.12M US dollars in net income (profit) last year or -$1.64 on an earnings per share basis.
What is Tourmaline Bio's stock symbol?

Tourmaline Bio, Inc. is traded on the NASDAQ under the ticker symbol "TRML".
What is Tourmaline Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Tourmaline Bio?

Shares of Tourmaline Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Tourmaline Bio have?

As Dec 2024, Tourmaline Bio employs 74 workers, which is 28% more then previous month and 68% more then previous quarter.
When Tourmaline Bio went public?

Tourmaline Bio, Inc. is publicly traded company for more then 4 years since IPO on 7 May 2021.
What is Tourmaline Bio's official website?

The official website for Tourmaline Bio is tourmalinebio.com.
Where are Tourmaline Bio's headquarters?

Tourmaline Bio is headquartered at 27 West 24th Street, New York, NY.
How can i contact Tourmaline Bio?

Tourmaline Bio's mailing address is 27 West 24th Street, New York, NY and company can be reached via phone at +64 6 481 9832.
What is Tourmaline Bio stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Tourmaline Bio in the last 12 months, the avarage price target is $50. The average price target represents a 123.51% change from the last price of $22.37.

Tourmaline Bio, Inc.

tourmalinebio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

+64 6 481 9832

27 West 24th Street
New York, NY 10010

CIK: 0001827506
ISIN: US89157D1054
: